Akari Therapeutics, Plc announced on December 18, 2024, the appointment of Samir R. Patel, M.D., as Chief Executive Officer, effective December 16, 2024. Dr. Patel had served as interim CEO since May 2024 and played a key role in the recent merger with Peak Bio.
Additionally, the company appointed Abizer Gaslightwala to its Board of Directors, effective December 16, 2024. Mr. Gaslightwala is a biotechnology and pharmaceutical industry leader with over 25 years of experience in developing and commercializing novel medicines.
Michael Grissinger, a member of the Board of Directors, provided notice of his resignation on December 16, 2024. These leadership changes are intended to streamline operations and execute on the company's portfolio prioritization, focusing on its Antibody-Drug Conjugate (ADC) platform.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.